Cargando…

Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma

BACKGROUND: Lenvatinib is a first-line agent for advanced hepatocellular carcinoma (HCC), but individual responses to treatment are highly heterogeneous. The aim of this study was to investigate the clinical parameters that influence the efficacy of Lenvatinib and to develop a prognostic model. METH...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xiaomi, Ding, Xiaoyan, Liu, Mei, Wang, Jingyan, Li, Wei, Chen, Jinglong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Hepatobiliary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546830/ https://www.ncbi.nlm.nih.gov/pubmed/37105140 http://dx.doi.org/10.1093/oncolo/oyad107

Ejemplares similares

Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy
por: Li, Xiaomi, et al.
Publicado: (2023)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
por: Li, Xiaomi, et al.
Publicado: (2023)

New concepts in the treatment of hepatocellular carcinoma
por: Sidali, Sabrina, et al.
Publicado: (2022)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients
por: Owusu Sekyere, Solomon, et al.
Publicado: (2021)

DCE-MRI-based radiomics in predicting angiopoietin-2 expression in hepatocellular carcinoma
por: Zheng, Jing, et al.
Publicado: (2023)

Dynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma
por: He, Guangming, et al.
Publicado: (2023)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

Association of Tumor Cell Metabolic Subtype and Immune Response With the Clinical Course of Hepatocellular Carcinoma
por: Wei, Xiaolin, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
por: Liu, Xiufeng, et al.
Publicado: (2019)

Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters
por: Sidali, Sabrina, et al.
Publicado: (2022)

The Comparison of Surgical Margins and Type of Hepatic Resection for Hepatocellular Carcinoma With Microvascular Invasion
por: Liu, Jianwei, et al.
Publicado: (2023)

Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
por: Woei‐A‐Jin, F.J. Sherida H., et al.
Publicado: (2021)

Real-world Treatment Patterns and Reasons for Therapy Selection in Patients with Advanced Hepatocellular Carcinoma in US Oncology Practices
por: Klink, Andrew J, et al.
Publicado: (2022)

Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma
por: Wang, Yuting, et al.
Publicado: (2023)

Nivolumab in Advanced Hepatocellular Carcinoma: Safety Profile and Select Treatment‐Related Adverse Events From the CheckMate 040 Study
por: Julien, Karen, et al.
Publicado: (2020)

Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance
por: Mähringer‐Kunz, Aline, et al.
Publicado: (2021)

Transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma: A systematic review
por: Norero, Blanca, et al.
Publicado: (2023)

Predicting the prognosis of hepatocellular carcinoma with the treatment of transcatheter arterial chemoembolization combined with microwave ablation using pretreatment MR imaging texture features
por: Liu, Jun, et al.
Publicado: (2021)

TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma
por: Lima, Henrique A., et al.
Publicado: (2022)

Exploring the efficacy of (18)F-FDG PET/CT in hepatocellular carcinoma diagnosis: role of Ki-67 index and tumor differentiation
por: Yin, Yuping, et al.
Publicado: (2023)

Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization
por: Müller, Lukas, et al.
Publicado: (2021)

High pretreatment static and dynamic alpha‐fetoprotein values predict reduced overall survival in hepatocellular carcinoma
por: Czauderna, Carolin, et al.
Publicado: (2021)

Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center
por: Motz, Victoria L., et al.
Publicado: (2021)

Response evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: magnetic resonance imaging findings
por: Mai, Zhijun, et al.
Publicado: (2023)

Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
por: Li, Xiaomi, et al.
Publicado: (2022)

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Fukushima, Taito, et al.
Publicado: (2023)

The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population‐based cohort study
por: Bengtsson, Bonnie, et al.
Publicado: (2022)

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
por: Pal Chaudhary, Surendra, et al.
Publicado: (2023)

Surgical Margin Affects the Long-Term Prognosis of Patients With Hepatocellular Carcinoma Undergoing Radical Hepatectomy Followed by Adjuvant TACE
por: Bai, Shilei, et al.
Publicado: (2023)

Improving detection performance of hepatocellular carcinoma and interobserver agreement for liver imaging reporting and data system on CT using deep learning reconstruction
por: Okimoto, Naomasa, et al.
Publicado: (2023)

Prognostic Relevance of a Complete Pathologic Response in Liver Transplantation for Hepatocellular Carcinoma
por: Grąt, Michał, et al.
Publicado: (2019)

Development and validation of a prognostic score for long‐term transplant‐free survival in autoimmune hepatitis type 1
por: Biewenga, Maaike, et al.
Publicado: (2021)

Toward a more precise prognostic stratification in acute decompensation of cirrhosis: The Padua model 2.0
por: Zanetto, Alberto, et al.
Publicado: (2023)

Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy: a systematic review and critical appraisal
por: Li, Li, et al.
Publicado: (2022)

Integrated prognostication of intrahepatic cholangiocarcinoma by contrast-enhanced computed tomography: the adjunct yield of radiomics
por: Silva, Mario, et al.
Publicado: (2021)

Added value of zoomed-echo-planar imaging diffusion-weighted imaging for evaluation of periampullary carcinomas
por: Liu, Jingjing, et al.
Publicado: (2023)

Evaluation of Abdominal Ultrasonography Mass Screening for Hepatocellular Carcinoma in Taiwan
por: Yeh, Yen-Po, et al.
Publicado: (2014)

Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study
por: Wei, Hong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l25uuevq4nrv8mvm6oqs36j8db